{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T17:33:33Z","timestamp":1746207213157},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s11239-022-02640-6","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T06:02:47Z","timestamp":1648015367000},"page":"605-615","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Post-thrombolytic coagulopathy and complications in patients with pulmonary embolism treated with fixed-dose systemic alteplase"],"prefix":"10.1007","volume":"54","author":[{"given":"Matthew P.","family":"Lillyblad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghaziuddin A.","family":"Qadri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brynn E.","family":"Weise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire S.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"St. Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Tierney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman R.","family":"Melamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"issue":"13","key":"2640_CR1","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1161\/circulationaha.107.726232","volume":"117","author":"S Laporte","year":"2008","unstructured":"Laporte S, Mismetti P, Decousus H et al (2008) Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation 117(13):1711\u20131716. https:\/\/doi.org\/10.1161\/circulationaha.107.726232","journal-title":"Circulation"},{"issue":"5","key":"2640_CR2","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.thromres.2015.09.012","volume":"136","author":"GY Gao","year":"2015","unstructured":"Gao GY, Yang P, Liu M et al (2015) Thrombolysis for acute intermediate-risk pulmonary embolism: A meta-analysis. Thromb Res 136(5):932\u2013937. https:\/\/doi.org\/10.1016\/j.thromres.2015.09.012","journal-title":"Thromb Res"},{"issue":"23","key":"2640_CR3","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/jama.2014.5990","volume":"311","author":"S Chatterjee","year":"2014","unstructured":"Chatterjee S, Chakraborty A, Weinberg I et al (2014) Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA 311(23):2414\u20132421. https:\/\/doi.org\/10.1001\/jama.2014.5990","journal-title":"JAMA"},{"issue":"5","key":"2640_CR4","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/0735-1097(92)90297-z","volume":"19","author":"P Tanswell","year":"1992","unstructured":"Tanswell P, Tebbe U, Neuhaus KL, Glasle-Schwarz L, Wojcik J, Seifried E (1992) Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol 19(5):1071\u20131075. https:\/\/doi.org\/10.1016\/0735-1097(92)90297-z","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2640_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","volume":"11","author":"AK Rao","year":"1988","unstructured":"Rao AK, Pratt C, Berke A et al (1988) Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11(1):1\u201311. https:\/\/doi.org\/10.1016\/0735-1097(88)90158-1","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"2640_CR6","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1212\/wnl.0b013e3182897015","volume":"80","author":"B Matosevic","year":"2013","unstructured":"Matosevic B, Knoflach M, Werner P et al (2013) Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis. Neurology 80(13):1216\u20131224. https:\/\/doi.org\/10.1212\/wnl.0b013e3182897015","journal-title":"Neurology"},{"issue":"8","key":"2640_CR7","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.03.021","volume":"23","author":"VH Lee","year":"2014","unstructured":"Lee VH, Conners JJ, Cutting S, Song SY, Bernstein RA, Prabhakaran S (2014) Elevated international normalized ratio as a manifestation of post-thrombolytic coagulopathy in acute ischemic stroke. J Stroke Cerebrovasc Dis 23(8):2139\u20132144. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2014.03.021","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"6","key":"2640_CR8","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1161\/01.str.0000126040.99024.cf","volume":"35","author":"P Trouillas","year":"2004","unstructured":"Trouillas P, Derex L, Philippeau F et al (2004) Early fibrinogen degradation coagulopathy is predictive of parenchymal hematomas in cerebral rt-PA thrombolysis: a study of 157 cases. Stroke 35(6):1323\u20131328. https:\/\/doi.org\/10.1161\/01.str.0000126040.99024.cf","journal-title":"Stroke"},{"issue":"2","key":"2640_CR9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J et al (2016) Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 149(2):315\u2013352. https:\/\/doi.org\/10.1016\/j.chest.2015.11.026","journal-title":"Chest"},{"issue":"4","key":"2640_CR10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2640_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.7326\/0003-4819-115-4-256","volume":"115","author":"EG Bovill","year":"1991","unstructured":"Bovill EG, Terrin ML, Stump DC et al (1991) Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 115(4):256\u2013265. https:\/\/doi.org\/10.7326\/0003-4819-115-4-256","journal-title":"Ann Intern Med"},{"issue":"2","key":"2640_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.09.005","volume":"24","author":"L Vandelli","year":"2015","unstructured":"Vandelli L, Marietta M, Gambini M et al (2015) Fibrinogen decrease after intravenous thrombolysis in ischemic stroke patients is a risk factor for intracerebral hemorrhage. J Stroke Cerebrovasc Dis 24(2):394\u2013400. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2014.09.005","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2640_CR13","doi-asserted-by":"publisher","unstructured":"Levine MN, Goldhaber SZ, Califf RM, Gore JM, Hirsh J (1992) Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest 102(4 Suppl):364S#x2013;373S. https:\/\/doi.org\/10.1378\/chest.102.4_supplement.364s","DOI":"10.1378\/chest.102.4_supplement.364s"},{"key":"2640_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3389\/fneur.2019.00513","volume":"10","author":"Z Bagoly","year":"2019","unstructured":"Bagoly Z, Szegedi I, Kalmandi R, Toth NK, Csiba L (2019) Markers of Coagulation and Fibrinolysis Predicting the Outcome of Acute Ischemic Stroke Thrombolysis Treatment: A Review of the Literature. Front Neurol 10:513. https:\/\/doi.org\/10.3389\/fneur.2019.00513","journal-title":"Front Neurol"},{"issue":"6","key":"2640_CR15","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1378\/chest.98.6.1473","volume":"98","author":"M Levine","year":"1990","unstructured":"Levine M, Hirsh J, Weitz J et al (1990) A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 98(6):1473\u20131479","journal-title":"Chest"},{"issue":"3","key":"2640_CR16","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1378\/chest.97.3.528","volume":"97","author":"Tissue plasminogen activator for the treatment of acute pulmonary embolism","year":"1990","unstructured":"Tissue plasminogen activator for the treatment of acute pulmonary embolism (1990) A collaborative study by the PIOPED Investigators. Chest 97(3):528\u2013533. https:\/\/doi.org\/10.1378\/chest.97.3.528","journal-title":"Chest"},{"issue":"3","key":"2640_CR17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/0735-1097(92)90002-5","volume":"20","author":"S Dalla-Volta","year":"1992","unstructured":"Dalla-Volta S, Palla A, Santolicandro A et al (1992) PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol 20(3):520\u2013526. https:\/\/doi.org\/10.1016\/0735-1097(92)90002-5","journal-title":"J Am Coll Cardiol"},{"issue":"8606","key":"2640_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/s0140-6736(88)92354-9","volume":"2","author":"SZ Goldhaber","year":"1988","unstructured":"Goldhaber SZ, Kessler CM, Heit J et al (1988) Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 2(8606):293\u2013298. https:\/\/doi.org\/10.1016\/s0140-6736(88)92354-9","journal-title":"Lancet"},{"issue":"1","key":"2640_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/0735-1097(92)90132-7","volume":"20","author":"SZ Goldhaber","year":"1992","unstructured":"Goldhaber SZ, Kessler CM, Heit JA et al (1992) Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol 20(1):24\u201330. https:\/\/doi.org\/10.1016\/0735-1097(92)90132-7","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2640_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0735-1097(92)90472-y","volume":"19","author":"G Meyer","year":"1992","unstructured":"Meyer G, Sors H, Charbonnier B et al (1992) Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. J Am Coll Cardiol 19(2):239\u2013245. https:\/\/doi.org\/10.1016\/0735-1097(92)90472-y","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2640_CR21","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1378\/chest.106.3.718","volume":"106","author":"SZ Goldhaber","year":"1994","unstructured":"Goldhaber SZ, Agnelli G, Levine MN (1994) Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group Chest 106(3):718\u2013724. https:\/\/doi.org\/10.1378\/chest.106.3.718","journal-title":"The Bolus Alteplase Pulmonary Embolism Group Chest"},{"issue":"7","key":"2640_CR22","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/oxfordjournals.eurheartj.a015410","volume":"18","author":"N Meneveau","year":"1997","unstructured":"Meneveau N, Schiele F, Vuillemenot A et al (1997) Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. Eur Heart J 18(7):1141\u20131148. https:\/\/doi.org\/10.1093\/oxfordjournals.eurheartj.a015410","journal-title":"Eur Heart J"},{"issue":"5","key":"2640_CR23","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/s0735-1097(98)00068-0","volume":"31","author":"N Meneveau","year":"1998","unstructured":"Meneveau N, Schiele F, Metz D et al (1998) Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. J Am Coll Cardiol 31(5):1057\u20131063. https:\/\/doi.org\/10.1016\/s0735-1097(98)00068-0","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2640_CR24","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1161\/01.cir.73.3.511","volume":"73","author":"D Collen","year":"1986","unstructured":"Collen D, Bounameaux H, De Cock F, Lijnen HR, Verstraete M (1986) Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation 73(3):511\u2013517. https:\/\/doi.org\/10.1161\/01.cir.73.3.511","journal-title":"Circulation"},{"issue":"1","key":"2640_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11239-015-1318-z","volume":"41","author":"S Vedantham","year":"2016","unstructured":"Vedantham S, Piazza G, Sista AK, Goldenberg NA (2016) Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism. J Thromb Thrombolysis 41(1):68\u201380. https:\/\/doi.org\/10.1007\/s11239-015-1318-z","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"2640_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.amjcard.2012.09.027","volume":"111","author":"M Sharifi","year":"2013","unstructured":"Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M, Investigators M (2013) Moderate pulmonary embolism treated with thrombolysis (from the \u201cMOPETT\u201d Trial). Am J Cardiol 111(2):273\u2013277. https:\/\/doi.org\/10.1016\/j.amjcard.2012.09.027","journal-title":"Am J Cardiol"},{"issue":"2","key":"2640_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1378\/chest.09-0765","volume":"137","author":"C Wang","year":"2010","unstructured":"Wang C, Zhai Z, Yang Y et al (2010) Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest 137(2):254\u2013262. https:\/\/doi.org\/10.1378\/chest.09-0765","journal-title":"Chest"},{"issue":"2","key":"2640_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/clpt.1989.120","volume":"46","author":"P Tanswell","year":"1989","unstructured":"Tanswell P, Seifried E, Su PC, Feuerer W, Rijken DC (1989) Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. Clin Pharmacol Ther 46(2):155\u2013162. https:\/\/doi.org\/10.1038\/clpt.1989.120","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2640_CR29","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1381\/096089206777346673","volume":"16","author":"HJ Lemmens","year":"2006","unstructured":"Lemmens HJ, Bernstein DP, Brodsky JB (2006) Estimating blood volume in obese and morbidly obese patients. Obes Surg 16(6):773\u2013776. https:\/\/doi.org\/10.1381\/096089206777346673","journal-title":"Obes Surg"},{"issue":"15","key":"2640_CR30","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/nejmoa021274","volume":"347","author":"S Konstantinides","year":"2002","unstructured":"Konstantinides S, Geibel A, Heusel G et al (2002) Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 347(15):1143\u20131150. https:\/\/doi.org\/10.1056\/nejmoa021274","journal-title":"N Engl J Med"},{"issue":"2","key":"2640_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/2042098615572333","volume":"6","author":"MJ Daley","year":"2015","unstructured":"Daley MJ, Murthy MS, Peterson EJ (2015) Bleeding risk with systemic thrombolytic therapy for pulmonary embolism: scope of the problem. Ther Adv Drug Saf 6(2):57\u201366. https:\/\/doi.org\/10.1177\/2042098615572333","journal-title":"Ther Adv Drug Saf"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-022-02640-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-022-02640-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-022-02640-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T09:11:55Z","timestamp":1667121115000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-022-02640-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["2640"],"URL":"https:\/\/doi.org\/10.1007\/s11239-022-02640-6","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,23]]},"assertion":[{"value":"9 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No conflicts of interest exist for the above mentioned authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research study was conducted retrospectively from data obtained for clinical purposes. We consulted with the IRB of Allina Health who determined that our study did not need ethical approval. An IRB official waiver of ethical approval was granted from the IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Matthew Lillyblad accepts official responsibility for the overall integrity of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor statement"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Names of collaborators"}},{"value":"The authors have no disclosures to report.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial\/nonfinancial disclosures"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the sponsors"}},{"value":"The authors would like to thank Barite Dawud for her contributions to the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Other contributions"}}]}}